A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Key Inclusion Criteria: Subject's written informed consent; 18-55 years of age; Ability to understand the study procedures, the risks involved and ability to be trained to use the inhalers correctly; Body Mass Index (BMI) between 18 and 32 kg/m2 extremes inclusive; Non- or ex-smokers who smoked < 5 pack years and stopped smoking > 1 year prior to screening; Good physical and mental status, determined on the basis of the medical history and a general clinical examination; Vital signs within normal limits at screening and prior to randomization: Diastolic BP 40-89 mmHg, Systolic BP 90-139 mmHg extremes included (mean value of three measures). Body temperature < 37.5°C; 12 -lead digitized Electrocardiogram (12-lead ECG) in triplicate considered as normal (40 ≤ Heart rate ≤ 110bpm, 120 ms ≤ PR ≤ 220 ms, QRS ≤ 110 ms, QTcF ≤ 450 ms); Lung function measurements within normal limits (normal values: forced expiratory volume in the 1st second [FEV1]/forced vital capacity [FVC] > 0.70 and FEV1 > 80% predicted); Female subjects of non-child bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods. Key Exclusion Criteria: Participation in another clinical trial where investigational drug was received and last investigations within the last 8 weeks; Clinically significant abnormal standard ECG at screening; Clinically relevant and uncontrolled respiratory, cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorders that may interfere with successful completion of this protocol; Subjects with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic; Subjects with history of breathing problems (i.e., history of asthma including childhood asthma); Positive urine test for cotinine; Intake of non-permitted concomitant medications in the predefined period prior to screening or prior to randomization, or the subject is expected to take non-permitted concomitant medications during the study; Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or to randomization; Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the trial; Women who are pregnant or lactating; Use of any kind of smoking electronic devices within 6 months before Screening. Other inclusion/exclusion criteria as defined by the protocol.